Phase 3 trial shows lurbinectedin plus atezolizumab significantly improves progression-free and overall survival in ES-SCLC ...

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing ...

Jazz Pharma and PharmaMar have revealed the overall survival (OS) data for their chemotherapy drug Zepzelca in ...

A new study is the first phase 3 to show meaningful improvement in both progression-free and overall survival with first-line ...

Maintenance therapy with lurbinectedin (lurbi) and atezolizumab (atezo) helps some patients with extensive-stage small cell ...

Exposure to wildfire smoke may increase lung cancer patients' risk of dying from their disease, particularly among ...

Outpatient tarlatamab administration for relapsed small cell lung cancer was feasible and safe with proper monitoring, according to findings presented at ASCO.

A recently-approved treatment could take a BiTE out of small cell lung cancer by using a person's own body to fight back.

Maintenance therapy with lurbinectedin (lurbi) and atezolizumab (atezo) helps some patients with extensive-stage small cell ...

The latest news from ASCO 2025 focusing on SCLC including abstracts, features, and helpful conference information.

AbbVie Inc. (NYSE:ABBV) has spotlighted major advancements in its oncology pipeline at the ASCO 2025 Annual Meeting, ...

PFS in Phase 3 HARMONi study was met with statistical significance, but OS was not. Click here to find out why SMMT stock is ...